Over 35 blockbuster branded pharmaceuticals to go off-patent in 2011 and 2012

26 January 2011

According to a brief published by the USA’s Office of the Assistant Secretary for Planning and Evaluation (ASPE), more than $209 billion in annual branded drug sales are projected to go off-patent between 2011 and 2014. Big name drugs projected to go off-patent include GlaxoSmithKline's Advair (fluticasone and salmeterol), Pfizer’s Viagra (sildenafil), Astra Zeneca’s Seroquel (quetiapine) and Symbicort (budesonide/formoterol), Eli Lily’s Zyprexa (olanzapine), Merck & Co’s Singulair (montelukast), and Forest Labs’ Lexapro (escitalopram oxalate).

Global projections for the international generic market are estimated to reach between $135 billion and $150 billion by 2015. BCC Research estimates the global market to reach $129.3 billion by 2014, representing a 9% annual growth rate. Goldman-Sachs Global Investment Research estimates that big names in the innovator drug market may lose up to 49% of their business to generic pharmaceutical companies by 2015.

Global copy sector to reach $100 billion in 2011

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK